rose ann scanlon

Director

Rose Ann is an Independent Director and C-suite executive with a track record of growing revenues and improving profitability by establishing and achieving strategic and operational goals, engaging team members, and strengthening customer relationships.  Her expertise is in biotech, pharmaceuticals, and healthcare at all sizes and stages.  She has a reputation for being an inspirational leader and strong strategic thinker with excellent judgment.  Rose Ann can effectively delegate and be as hands-on as needed. 

She most recently served as CEO of a confidential biotech company where she launched a business transformation from an R&D focus to a commercial business and prepared the company for a pending IPO.  Prior to that role, she was COO of Zelira Therapeutics (ASX:ZLD), a global biopharmaceutical company.  As employee #2, she established the organization’s infrastructure and led the development and launch of six products in the biotech’s first 19 months, including a novel, patent-pending, five-product division. 

Before joining Zelira, Rose Ann co-founded and Chaired Scanlon.Louis, a global business strategy and execution firm. She built it from start-up to one of the fastest-growing companies in Philadelphia (2012 Philadelphia 100).  At Scanlon.Louis, she was engaged as an interim executive by a number of companies.  She significantly impacted her clients’ businesses, including reversing a multi-year sales decline and significantly improving profitability while facing decreased reimbursement rates at one firm, and growing a healthcare start-up by 1500%+ in 6 months while improving patient outcomes by 30% and increasing customer satisfaction by 4x.  Before Scanlon.Louis, Rose Ann spent 19 years at AstraZeneca, serving in executive roles in legal, regulatory affairs, sales, and commercial operations.  Her accomplishments included increasing revenue by $250M by accelerating time-to-market, increasing revenue by $20M in 3 months by improving customer sampling, and turning around a failing oncology franchise.

Rose Ann’s board experience includes serving as an Independent Director at Moro Corporation. (NQB: MRCR); and as an Independent Trustee at Redeemer Health.  She has also served on and chaired several charitable organization boards. 

Rose Ann has a J.D. from Villanova, and a B.S., cum laude, from Delaware.  Recognitions include: